EUVIMEDEUVIMED entdecken
Crossref

Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?

Imen Zawati, Yousra Troujette, Olfa Adouni, Maroua Manai, Meriem Nouira, Karim Mekki, Mohamed Manai, Khaled Rahal, Amor Gamoudi

Pathology · 2025-08 · 57 (5) · 570-578

DOI: 10.1016/j.pathol.2024.11.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology, 2025-08. Verfasst von Imen Zawati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Department of Biology, Laboratory of Biochemistry and Molecular Biology,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm, Residual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ministère de l’Enseignement Supérieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication, Université de Tunis El Manar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Residual proliferative cancer burden (RPCB) has been suggested as a strong predictor model of long-term outcomes in breast cancer undergoing neoadjuvant chemotherapy (NACT). In our study, we aimed to compare the prognostic value of multiple post-NACT classifications for assessing residual disease. Archival surgical specimens of 97 patients with primary breast cancer who underwent NACT were evaluated for residual cancer burden (RCB). The post-operative Ki-67 proliferation index was quantified using immunohistochemistry on post-treatment surgical excision specimens with residual disease. Then, we calculated the RPCB scores by combining the anatomical RCB index with the biological post-therapeutic Ki-67 using the Cox proportional hazard model for each parameter. Using the Kaplan-Meier method, RCBIII showed an unfavourable prognosis with worse relapse-free survival (RFS) (estimated 5-year RFS rate of 38%) than RCBI, which displayed a similarly good prognosis as pathological complete response (equal to RCB0) (estimated 5-year RFS rates of 80% and 100%, respectively) (p=0.012). The RCBII showed an intermediate prognosis (estimated 5-year RFS rate of 79%). A higher post-NACT Ki-67 (greater than cut-off 20%) had a negative impact on the overall survival and RFS (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm, ResidualHumansFemaleNeoadjuvant TherapyMiddle AgedAdultPrognosisAgedKi-67 AntigenDisease-Free SurvivalChemotherapy, AdjuvantKaplan-Meier EstimateTreatment OutcomeTumor Burden

Stichwörter der Autor:innen

breast cancerneoadjuvant chemotherapyprognosisresidual cancer burdenresidual diseaseresidual proliferative cancer burden

Substanzen

Ki-67 Antigen

Autor:innen und Institutionen

  • Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Department of Biology, Laboratory of Biochemistry and Molecular Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, T…
  • Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia.
  • Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Laboratory of Transmission, Control and Immunobiology of Infections - LR16IPT02, Pasteur Institute of Tunis, University of Tunis, Tunis, Tunis…
  • Department of Epidemiology and Community Medicine, Charles Nicoles Hospital, Tunis, Tunisia.
  • Institut Pascal Clermont-Ferrand, France.
  • Department of Biology, Laboratory of Biochemistry and Molecular Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia.

Förderung

  • Ministère de l’Enseignement Supérieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication
  • Université de Tunis El Manar

Zitieren

APA

Zawati, I., Troujette, Y., Adouni, O., Manai, M., Nouira, M., Mekki, K., Manai, M., Rahal, K., & Gamoudi, A. (2025). Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?. Pathology, 57(5), 570-578. https://doi.org/10.1016/j.pathol.2024.11.014

Vancouver

Zawati I, Troujette Y, Adouni O, Manai M, Nouira M, Mekki K, et al. Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?. Pathology. 2025;57(5):570-578. doi:10.1016/j.pathol.2024.11.014

BibTeX
@article{Zawati2025,
  author = {Zawati, Imen and Troujette, Yousra and Adouni, Olfa and Manai, Maroua and Nouira, Meriem and Mekki, Karim and Manai, Mohamed and Rahal, Khaled and Gamoudi, Amor},
  title = {Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?},
  journal = {Pathology},
  year = {2025},
  volume = {57},
  number = {5},
  pages = {570--578},
  doi = {10.1016/j.pathol.2024.11.014}
}
Kostenlos starten →